Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant

@article{Fernandes2006AnalysisOS,
  title={Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant},
  author={Nat{\'e}rcia Em{\'i}lia Pedro Fernandes and Paula Alvarenga de Figueiredo and Virg{\'i}lio Est{\'o}lio do Ros{\'a}rio and Pedro V L Cravo},
  journal={Malaria Journal},
  year={2006},
  volume={6},
  pages={35 - 35}
}
Plasmodium falciparum is the predominant human malaria species in Mozambique and a lead cause of mortality among children and pregnant women nationwide. Sulphadoxine/pyrimethamine (S/P) is used as first line antimalarial treatment as a partner drug in combination with artesunate. A total of 92 P. falciparum-infected blood samples, from children with uncomplicated malaria attending the Centro de Saude de Bagamoyo in the Province of Maputo-Mozambique, were screened for S/P resistance-conferring… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania.

Transactions of the Royal Society of Tropical Medicine and Hygiene • 2002
View 12 Excerpts
Highly Influenced

Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet?

Transactions of the Royal Society of Tropical Medicine and Hygiene • 2005
View 2 Excerpts

The mechanisms of resistance toantimalarial drugs in Plasmodium falciparum

J Le Bras, R Durand
Fundam Clin Pharmacol • 2003
View 1 Excerpt

Similar Papers

Loading similar papers…